The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. reported strong first-quarter 2026 growth with a smaller loss. Revenue rose to $78.0 million, up 42% from $55.0 million a year earlier, driven by a 51% increase in average members and higher hardware shipments. Services revenue reached $69.6 million and hardware revenue $8.5 million.
Gross profit increased to $48.7 million and gross margin expanded to 62.4%, helped by efficiency initiatives in Care Team operations and supporting technology. The net loss narrowed to $3.0 million from $9.4 million, while cash and cash equivalents remained high at $211.8 million. Total members reached 1,025,000 as of March 31, 2026.
Omada Health reported strong first-quarter 2026 growth with improving profitability metrics. Revenue reached $78.0 million for the three months ended March 31, 2026, up 42% year over year, while Total Members grew to 1.02 million, a 51% increase, highlighting expanding adoption of its virtual cardiometabolic care platform.
GAAP gross margin improved to 62%, and non-GAAP gross margin to 64%. Net loss narrowed to $3.0 million from $9.4 million a year earlier, and adjusted EBITDA turned positive at $0.9 million versus a $4.2 million loss. Omada ended the quarter with $211.8 million of cash and cash equivalents and raised its full-year 2026 revenue and adjusted EBITDA outlook.
Omada Health reported strong first-quarter 2026 growth with improving profitability metrics. Revenue reached $78.0 million for the three months ended March 31, 2026, up 42% year over year, while Total Members grew to 1.02 million, a 51% increase, highlighting expanding adoption of its virtual cardiometabolic care platform.
GAAP gross margin improved to 62%, and non-GAAP gross margin to 64%. Net loss narrowed to $3.0 million from $9.4 million a year earlier, and adjusted EBITDA turned positive at $0.9 million versus a $4.2 million loss. Omada ended the quarter with $211.8 million of cash and cash equivalents and raised its full-year 2026 revenue and adjusted EBITDA outlook.
Omada Health Inc. filing an amendment to Schedule 13G/A discloses that FMR LLC beneficially owned 3,288,380 shares of Omada common stock, representing 5.6% of the class as of 03/31/2026. The filing lists sole dispositive power for 3,288,380 shares and references an Exhibit 99 13d-1(k) agreement and a power of attorney.
The filing is an ownership disclosure by an institutional investor under Schedule 13G/A and does not state any transaction activity or changes in holdings beyond the reported position.
Omada Health, Inc. is asking stockholders to vote at its 2026 virtual Annual Meeting on June 16, 2026. Owners of common stock at the April 20, 2026 record date, when 59,415,251 shares were outstanding, are entitled to one vote per share.
Stockholders will vote on electing Sean Duffy and Trevor Fetter as Class I directors through the 2029 meeting and on ratifying Deloitte & Touche LLP as independent auditor for 2026. The proxy also reviews 2025 governance, committee activity, and executive pay, including salary, bonus, stock options, and RSUs.
Omada Health, Inc. President Wei-Li Shao sold shares in a planned open-market transaction. On April 8, 2026, Shao sold 2,829 shares of Omada Health Common Stock at a weighted average price of $12.7062 per share in an open-market sale. After this transaction, Shao directly owns 328,850 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 15, 2025, indicating the trade was pre-arranged rather than a discretionary market-timed decision.
Omada Health, Inc. director Jeryl L. Hilleman received an equity grant in the form of restricted stock units. The filing reports an acquisition of 1,544 shares of Common Stock at a stated price of $0.00 per share, classified as a grant or award rather than a market purchase.
The RSUs were granted under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents the right to receive one share of Common Stock upon settlement. After this award, Hilleman directly holds 14,338 shares of Omada Health common stock.
ROOT JONATHAN D reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Jonathan D. Root received an equity award of 882 shares of Common Stock in the form of restricted stock units granted under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents one share of Common Stock, to be settled on a date chosen by the director under the program or as otherwise specified by the program. Following this grant, he directly holds 180,175 shares of Common Stock. This is a compensation-related award, not an open-market purchase.
Klapstein Julie D reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Julie D. Klapstein received an award of 698 shares of Common Stock in the form of restricted stock units (RSUs). The RSUs were granted under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees and carry a grant price of $0.00 per share.
Each RSU represents the right to receive one share of Common Stock, with settlement to occur on a date selected by the director or as otherwise provided by the program. Following this compensatory grant, Klapstein’s direct holdings total 10,434 shares of Common Stock reported in this filing.